International Immunology Advance Access published online on July 2, 2007
International Immunology, doi:10.1093/intimm/dxm057
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PD-1 and PD-1 ligands: from discovery to clinical application
1 21st Century Center of Excellence Formation
2 Department of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University, Yoshida-Konoe, Sakyo-ku, Kyoto 606-8501, Japan
Correspondence to: Correspondence to: T. Honjo; E-mail: honjo{at}mfour.med.kyoto-u.ac.jp
Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases.
Keywords: Costimulation, Autoimmunity, Tumor immunity, Viral infection, SNP
Received 9 February 2007, accepted 23 April 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Jiang, T. Yoshida, F. Nakaki, S. Terawaki, S. Chikuma, Y. Kato, I.-m. Okazaki, T. Honjo, and T. Okazaki Identification of QTLs that modify peripheral neuropathy in NOD.H2b-Pdcd1-/- mice Int. Immunol., May 1, 2009; 21(5): 499 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. V. Parekh, S. Lalani, S. Kim, R. Halder, M. Azuma, H. Yagita, V. Kumar, L. Wu, and L. Van Kaer PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells J. Immunol., March 1, 2009; 182(5): 2816 - 2826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Gao, X.-Y. Wang, S.-J. Qiu, I. Yamato, M. Sho, Y. Nakajima, J. Zhou, B.-Z. Li, Y.-H. Shi, Y.-S. Xiao, et al. Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma Clin. Cancer Res., February 1, 2009; 15(3): 971 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Yang, H. Li, P. W. Chen, H. Alizadeh, Y. He, R. N. Hogan, and J. Y. Niederkorn PD-L1 Expression on Human Ocular Cells and Its Possible Role in Regulating Immune-Mediated Ocular Inflammation Invest. Ophthalmol. Vis. Sci., January 1, 2009; 50(1): 273 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Marzec, Q. Zhang, A. Goradia, P. N. Raghunath, X. Liu, M. Paessler, H. Y. Wang, M. Wysocka, M. Cheng, B. A. Ruggeri, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) PNAS, December 30, 2008; 105(52): 20852 - 20857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Lucas, J. Menke, W. A. Rabacal, F. J. Schoen, A. H. Sharpe, and V. R. Kelley Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice J. Immunol., August 15, 2008; 181(4): 2513 - 2521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lazar-Molnar, Q. Yan, E. Cao, U. Ramagopal, S. G. Nathenson, and S. C. Almo From the Cover: Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2 PNAS, July 29, 2008; 105(30): 10483 - 10488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Freeman Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek PNAS, July 29, 2008; 105(30): 10275 - 10276. [Full Text] [PDF]
|
|
|
|
|
|
W. Yang, P. W. Chen, H. Li, H. Alizadeh, and J. Y. Niederkorn PD-L1: PD-1 Interaction Contributes to the Functional Suppression of T-Cell Responses to Human Uveal Melanoma Cells In Vitro Invest. Ophthalmol. Vis. Sci., June 1, 2008; 49(6): 2518 - 2525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Y.-w. Lin, Y. Tanaka, M. Iwasaki, A. G. Gittis, H.-P. Su, B. Mikami, T. Okazaki, T. Honjo, N. Minato, and D. N. Garboczi The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors PNAS, February 26, 2008; 105(8): 3011 - 3016. [Abstract] [Full Text] [PDF]
|
|